AstraZeneca wins two approval recommendations from EU agency Oxford University says Covid-19 patients experience symptoms months after contracting virus
CNN: The European medicines watchdog has recommended approving AstraZeneca Plc’s AZN.L treatments for a form of heart failure and a lung disorder, the British drugmaker said on Monday. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approving Forxiga for treating a form of heart failure and Trixeo Aerosphere for a form of lung disorder known as “smoker’s lung”.Britain’s Oxford University said on Monday initial findings from a study on the long term impact of Covid-19 has found that a large number of patients discharged from hospitals still experience symptoms of breathlessness, fatigue, anxiety and depression two to three months after contracting the virus. After emerging last year in China which was then followed by a massive loss of lives across the globe, the novel coronavirus has crossed another grim milestone with the confirmed infections surpassing 40 million on Monday.The United Nations said Monday it would stockpile one billion syringes around the world by the end of 2021, to be used for the delivery of any future coronavirus vaccine. UNICEF, the UN Children’s Fund, said it aims to get 520 million syringes in its warehouses by the end of this year, to guarantee an initial supply in countries ahead of the
“The world will need as many syringes as doses of vaccine,” UNICEF said in a statement.
UNICEF said it was also buying five million safety boxes for used syringes.
The number of confirmed coronavirus cases worldwide passed 40 million on Monday, according to an AFP tally based on official sources. More than 1.1 million deaths have been recorded across the globe.
“Vaccinating the world against Covid-19 will be one of the largest mass undertakings in human history, and we will need to move as quickly as the vaccines can be produced,” said UNICEF executive director Henrietta Fore.
“By the end of the year, we will already have over half a billion syringes pre-positioned where they can be deployed quickly and cost effectively.”